Vivani Medical Inc. has announced promising results from their recent study involving an exenatide implant designed to reduce liver fat and manage body weight. The study, which was presented in a recent Form 8-K filing, demonstrated that the exenatide implant reduced liver fat by 82% in obese mice after 12 weeks. The findings were consistent with previous investigations using semaglutide injections. Additionally, the exenatide implant, delivered using NanoPortal™ technology, showed durable effects on body weight in healthy Sprague-Dawley rats over a period of 105 days, with some subjects observed for up to 112 days followed by a recovery period. These results highlight the potential of the exenatide implant in addressing obesity-related conditions.
免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。